[1] |
CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing.
Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
|
[2] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
[3] |
CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun.
Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
|
[4] |
LEI Jianlin, WANG Na, WANG Wenzheng, WANG Yan.
One Case of Phenytoin Intoxication Caused by Compound Phenytoin Sodium Ephedrine Hydrochloride and Theophylline Tablets
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 819-822.
|
[5] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[6] |
LI Dong, ZHAO Yan.
Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 640-644.
|
[7] |
ZHU Lei, ZHANG Xian, WANG Ruiyan, LI Ying.
Adverse Reactions Reports about Tislelizumab Injection in 447 Cases
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 649-653.
|
[8] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[9] |
FU Weiran, ZOU Dongmei, NI Jing, SUN Wanling, GUO Yixian.
Short-Term Efficacy and Safety of Thiotepia-based Conditioning Regimen Combined with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Primary Central Nervous System Lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 664-668.
|
[10] |
ZHENG Kaifan, LENG Hongxu, XU Kaixuan, CAI Wenlu, ZHANG Ying, ZHAO Pengfei, TAN Shengjie, XIN Guizhong.
Research Progress on Intestinal Safety of Anthraquinone Laxatives
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 708-713.
|
[11] |
LIU Lianlian, YU Huiyong, WANG Mingzhe, GUO Shanshan, LI Lei, GAO Yue, WEI Shixiang, KE Yinze, WANG Chengxiang.
TCM Medications for Pulmonary Nodules Based on Traditional Chinese Medicine Inheritance Assistance System
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 513-516.
|
[12] |
WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping.
Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579.
|
[13] |
MENG Xianghui, SUN Jiabei, Li Wenlong, JIA Juanjuan, CHENG Ming, HUANG Haiwei, SHI Yaqin.
Zebrafish Toxicity of Trimethylsilanol: an Introduced Impurity in Fludeoxyglucose [18F] Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 397-402.
|
[14] |
YANG Jingqi, XU Baohai, ZHANG Jing, JIANG Yang, SHI Fang.
Pharmacovigilance for Traditional Chinese Patent Medicines for Orthopedics
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 436-441.
|
[15] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|